Chronic hepatitis C virus infection and lipoprotein metabolism

被引:53
作者
Aizawa, Yoshio [1 ]
Seki, Nobuyoshi [1 ]
Nagano, Tomohisa [1 ]
Abe, Hiroshi [1 ]
机构
[1] Jikei Univ, Katsushika Med Ctr, Dept Internal Med, Tokyo 1258506, Japan
关键词
Hepatitis C virus; Apolipoprotein; Lipo-viral particle; Dyslipoproteinemia; Lipoprotein; FATTY-ACID SYNTHASE; APOLIPOPROTEIN-E; COMBINATION THERAPY; LIPOVIRAL PARTICLES; LIPID-METABOLISM; LIFE-CYCLE; VIROLOGICAL RESPONSE; DENSITY-LIPOPROTEINS; INSULIN-RESISTANCE; RNA REPLICATION;
D O I
10.3748/wjg.v21.i36.10299
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) is a hepatotrophic virus and a major cause of chronic liver disease, including hepatocellular carcinoma, worldwide. The life cycle of HCV is closely associated with the metabolism of lipids and lipoproteins. The main function of lipoproteins is transporting lipids throughout the body. Triglycerides, free cholesterol, cholesteryl esters, and phospholipids are the major components of the transported lipids. The pathway of HCV assembly and secretion is closely linked to lipoprotein production and secretion, and the infectivity of HCV particles largely depends on the interaction of lipoproteins. Moreover, HCV entry into hepatocytes is strongly influenced by lipoproteins. The key lipoprotein molecules mediating these interactions are apolipoproteins. Apolipoproteins are amphipathic proteins on the surface of a lipoprotein particle, which help stabilize lipoprotein structure. They perform a key role in lipoprotein metabolism by serving as receptor ligands, enzyme co-factors, and lipid transport carriers. Understanding the association between the life cycle of HCV and lipoprotein metabolism is important because each step of the life cycle of HCV that is associated with lipoprotein metabolism is a potential target for anti-HCV therapy. In this article, we first concisely review the nature of lipoprotein and its metabolism to better understand the complicated interaction of HCV with lipoprotein. Then, we review the outline of the processes of HCV assembly, secretion, and entry into hepatocytes, focusing on the association with lipoproteins. Finally, we discuss the clinical aspects of disturbed lipid/lipoprotein metabolism and the significance of dyslipoproteinemia in chronic HCV infection with regard to abnormal apolipoproteins.
引用
收藏
页码:10299 / 10313
页数:15
相关论文
共 134 条
[1]  
Aizawa Y, 2012, LIPOPROTEINS - ROLE IN HEALTH AND DISEASES, P701, DOI 10.5772/48117
[2]   Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C [J].
Aizawa, Yoshio ;
Yohizawa, Kai ;
Aida, Yuta ;
Ishiguro, Haruya ;
Abe, Hiroshi ;
Tsubota, Akihito .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2012, 360 (1-2) :9-14
[3]   Role of low-density lipoprotein receptor in the hepatitis C virus life cycle [J].
Albecka, Anna ;
Belouzard, Sandrine ;
de Beeck, Anne Op ;
Descamps, Veronique ;
Goueslain, Lucie ;
Bertrand-Michel, Justine ;
Terce, Francois ;
Duverlie, Gilles ;
Rouille, Yves ;
Dubuisson, Jean .
HEPATOLOGY, 2012, 55 (04) :998-1007
[4]   Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection [J].
Andreo, Ursula ;
Maillard, Patrick ;
Kalinina, Olga ;
Walic, Marine ;
Meurs, Eliane ;
Martinot, Michele ;
Marcellin, Patrick ;
Budkowska, Agata .
CELLULAR MICROBIOLOGY, 2007, 9 (10) :2445-2456
[5]   Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C [J].
Atsukawa, Masanori ;
Tsubota, Akihito ;
Shimada, Noritomo ;
Abe, Hiroshi ;
Kondo, Chisa ;
Itokawa, Norio ;
Nakagawa, Ai ;
Iwakiri, Katsuhiko ;
Kawamoto, Chiaki ;
Aizawa, Yoshio ;
Sakamoto, Choitsu .
DIGESTIVE AND LIVER DISEASE, 2014, 46 (08) :738-743
[6]   Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b [J].
Atsukawa, Masanori ;
Tsubota, Akihito ;
Kondo, Chisa ;
Itokawa, Norio ;
Narahara, Yoshiyuki ;
Nakatsuka, Katsuhisa ;
Hashimoto, Satomi ;
Fukuda, Takeshi ;
Matsushita, Yoko ;
Kidokoro, Hideko ;
Kobayashi, Tamaki ;
Kanazawa, Hidenori ;
Sakamoto, Choitsu .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (01) :51-56
[7]   A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients [J].
Bader, T. ;
Hughes, L. D. ;
Fazili, J. ;
Frost, B. ;
Dunnam, M. ;
Gonterman, A. ;
Madhoun, M. ;
Aston, C. E. .
JOURNAL OF VIRAL HEPATITIS, 2013, 20 (09) :622-627
[8]   Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets [J].
Barba, G ;
Harper, F ;
Harada, T ;
Kohara, M ;
Goulinet, S ;
Matsuura, Y ;
Eder, G ;
Schaff, Z ;
Chapman, MJ ;
Miyamura, T ;
Brechot, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1200-1205
[9]   Assembly of infectious hepatitis C virus particles [J].
Bartenschlager, Ralf ;
Penin, Francois ;
Lohmann, Volker ;
Andre, Patrice .
TRENDS IN MICROBIOLOGY, 2011, 19 (02) :95-103
[10]   Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate [J].
Barth, H ;
Schäfer, C ;
Adah, MI ;
Zhang, FM ;
Linhardt, RJ ;
Toyoda, H ;
Kinoshita-Toyoda, A ;
Toida, T ;
van Kuppevelt, TH ;
Depla, E ;
von Weizsäcker, F ;
Blum, HE ;
Baumert, TF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41003-41012